مباشر

FierceBiotechTravere scales Everest with $1.1B deal for BTK inhibitor aimed at rare kidney diseases Endpoints NewsMale contraception startup closes $92.5M Series B; Novartis bets on actinium Endpoints NewsTravere pays Everest $112M upfront to grow rare kidney disease pipeline Endpoints NewsLegend Biotech shares first in vivo CAR-T data, its next act after Carvykti FierceBiotechFulcrum scraps SCD program, considers options after FDA takes hard line on safety risks FierceBiotechASCO: Cardiff posts updated colorectal cancer data ahead of pivotal push PharmaVoiceAs amyloid falls out of favor, here’s where Alzheimer’s R&D is headed next BioWorldJanssen Pharmaceutica reports new TMEM175 activators BioWorldBlossomhill Therapeutics discovers new EGFR mutant inhibitors BioWorldChina Pharmaceutical University discloses new asiaticoside saponin compounds BioWorldWigen Biomedicine Technology patents new GTPase KRAS inhibitors LabiotechThe biggest biotech funding rounds in May 2026

FierceBiotech ٢ يونيو ٢٠٢٦

ASCO: Celcuity dares to dream of becoming $10B company after breast cancer win over Piqray

While Revolution Medicines dominated this year’s American Society of Clinical Oncology annual meeting by conquering the “undruggable” RAS pathway, another up-an...

While Revolution Medicines dominated this year’s American Society of Clinical Oncology annual meeting by conquering the “undruggable” RAS pathway, another up-and-coming biotech hopes to do the same with a different vexing target that drives a plethora of cancers.